Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.40 |
| ▸ | CTSL | P07711 | 8/20 | 0.40 |
| ▸ | CTSK | P43235 | 6/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841917 | 0.90 | PARP10 (0.39) | PARP10ALDH1A1POLBCDK2SIRT2 | |
| SCHEMBL3017456 | 0.84 | RAB9A (0.40) | CTSSCTSLPARP10POLBSIRT2 | |
| SCHEMBL5843360 | 0.83 | CTSS (0.53) | CTSSCTSLCTSKKDM4EALDH1A1 | |
| SCHEMBL3019566 | 0.74 | CTSS (0.39) | CTSSCTSLCTSKEPHX1EPHX2 | |
| SCHEMBL5264007 | 0.71 | CHEK1 (0.43) | KDM4EALDH1A1POLBCDK2EPHX2 | |
| SCHEMBL4796161 | 0.70 | CTSL (0.43) | CTSSCTSLCTSKEPHX1 | |
| SCHEMBL4800843 | 0.70 | CTSS (0.51) | CTSSCTSLCTSKKDM4EALDH1A1 | |
| SCHEMBL6685716 | 0.69 | KDM4E (0.47) | CTSSCTSLCTSKKDM4EALDH1A1 | |
| SCHEMBL6689992 | 0.68 | CFD (0.41) | KDM4EALDH1A1POLBSIRT2EPHX1 | |
| SCHEMBL3022158 | 0.68 | CTSS (0.49) | CTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | claimed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | CTSS 1/4885CTSL 10/4885CTSK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.